

Clinical effects of mindfulness meditation and cognitive behavioral therapy standardized for insomnia

A protocol for a systematic review and meta-analysis

Moon Joo Cheong, PhD^a, Go-Eun Lee, KMD, PhD^b, Hyung Won Kang, KMD, PhD^{c,*}, Sooim Kim, PhD^d, Hye Kyung Kim, PhD^e, Han-ik Jo, PhD^a, Yeonseok Kang, KMD, PhD^f, Jae-Hyo Kim, KMD, PhD^g, Hyeon-Gi Baek, PhD^h

Abstract

Introduction: This systematic review protocol describes the methods that will be used to evaluate the efficacy and safety of mindfulness meditation and cognitive behavioral therapy programs as a psychological intervention for insomnia disorders.

Methods and analysis: We will search the following 11 electronic databases without language or publication status restrictions: MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, Allied and Complementary Medicine Database, Cumulative Index to Nursing and Allied Health Literature, and PsycARTICLES. Furthermore, we will also search 5 Korean-language databases (Oriental Medicine Advanced Searching Integrated System, Korean studies Information Service System, Research Information Service System, Korean Medical Database, and Korea Citation Index). The study selection and data extraction will be performed independently by 2 authors. The study quality assessment and evaluation of the quality of evidence for the main findings will be performed independently by 2 authors using the Cochrane tool for assessing risk of bias and predefined criteria (the Grading of Recommendations Assessment, Development, and Evaluation approach). Data synthesis and analysis will be performed using RevMan Version 5.3. Data will be synthesized by either a fixed effects or random effects model according to a heterogeneity test or the number of studies included in the meta-analysis. If any plan for documenting important protocol amendments changes, the researchers will have a revision agreement and then register the modification in the International Prospective Register of Systematic Reviews (PROSPERO).

Ethics and dissemination: Ethical approval will not be required because individual patient data are not included and because this protocol is for a systematic review. The findings of this systematic review will be disseminated through conference presentations. PROSPERO registration number: CRD42018111217.

Abbreviations: CBT = cognitive behavioral therapy, DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, MBSR = mindfulness-based stress reduction, MM = mindfulness-based meditation, PROSPERO = International Prospective Register of Systematic Reviews.

Keywords: cognitive behavioral therapy, insomnia disorder, mindfulness meditation, protocol, systematic review

MJC and G-EL contributed equally to this work (co-first authors).

This research was supported by the research program of the Korea Institute of Oriental Medicine (K18900).

The authors have no conflicts of interest to declare.

^a Education Graduate of Hanyang University, ^b Department of Oriental Rehabilitation Medicine, Korean National Rehabilitation, Seoul, ^c Department of Korean Neuropsychiatry Medicine & Inam Neuroscience Research Center, Wonkwang University Sanbon Hospital, Gunpo, ^d Department of Clinical Counseling Psychology, CHA University, ^e Department of Counseling Psychology, Hankuk University of Foreign Studies, Seoul, ^f Department of Medical History, ^g Department of Meridian & Acupoint, College of Korean Medicine, ^h The Institute of Mind Humanities, Wonkwang University, Iksan, Republic of Korea.

* Correspondence: Hyung Won Kang, Department of Neuropsychiatry of Korean Medicine & Inam Neuroscience Research Center, Wonkwang University Sanbon hospital 321, Sanbon-ro Gunpo City, Gyeonggi-do 15865, Republic of Korea (e-mail: dskhw@wku.ac.kr).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97:51(e13499)

Received: 7 November 2018 / Accepted: 9 November 2018

<http://dx.doi.org/10.1097/MD.0000000000013499>

1. Introduction

Healthy sleep for humans restores function and vitality, promotes memory integration, and maintains immune function. Nonetheless, 10% to 12% of the world's population experience sleep disorders because of a variety of causes.^[1] In Korea, the number of patients with insomnia has increased by 40.19% over the past 5 years^[2] and the average sleep time in Korea was 7 hours and 41 minutes, the lowest among Organisation for Economic Co-operation and Development countries.^[3] Individuals who experience sleeplessness more than 3 times a week now account for over 17.0% of the population.^[1,4]

According to National Health Insurance Corporation data, the number of patients who have been treated for insomnia for the past 5 years (2013–2017) has exceeded 2 million, and the total cost of the treatment was estimated to be about 204.6 billion won in Korea.^[4] This is not very different from other countries.^[5,6] According to the National Sleep Foundation Survey, from 2013 to 2015, 51% of US adults have at least one symptom associated with insomnia.^[7] The US also has an annual expenditure of \$107 to \$920 billion for treating insomnia.^[8,9] In Canada, it was found to cost \$5000 per treatment.^[10] As such, insomnia has a high

burden for the individual and society because of the high cost of evaluation and treatment. Nonetheless, patients who currently have insomnia are predominantly prescribed medications that can be abused by patients with chronic insomnia or can increase resistance-dependence, creating problems other than insomnia.^[11] Untreated insomnia also increases the risk of heart disease, motor vehicle accidents, memory disorders, depression, and dysfunction.^[12,13] Without appropriate intervention, it can last for years after its development and the probability of other comorbid psychiatric disorders increases.^[14,15]

Recently, a variety of programs using a psychological intervention have been used to increase the quality of life of patients with insomnia and to reduce the adverse effects of drugs in place of simple drug prescriptions.^[16] Some patients experiencing sleeplessness may also have psychological problems with a behavioral aspect such as insomnia.^[17] Typical psychological intervention programs include cognitive behavioral therapy (CBT)^[18,19] and meditation programs^[20,21] based on mindfulness, which are widely used and have demonstrated their efficacy in many places.

In particular, CBT aims to reduce the cognitive physiologically elevated arousal level, correct maladaptive sleep habits, and modify dysfunctional beliefs and attitudes toward sleep.^[18]

Thus, recently, many patients with insomnia have a preference for CBT over drug therapy with its risk of increasing dependence and side effects. In addition, the mindfulness-based meditation (MM) program,^[20,21] Kabat-Zinn's "Mindfulness-Based Stress Reduction" (MBSR),^[22,23] and meditation on sleep disturbances in cancer patients has been shown to improve sleep quality^[24] and efficiency. Through a comparative study of medication- and mindfulness meditation use in groups of cancer patients,^[25] it has been reported that meditation has a more positive effect on the improving sleep quality relative to drug treatment. In addition, research on mindfulness, well-being, and sleeping has consistently proven that mindfulness has a significant influence on improving sleep quality and quality of life.^[26]

Therefore, this study will systematically examine the effects of psychological treatment interventions, such as CBT and MM therapy, which both demonstrate that the mind is correlated with behavior, on sleep disorders. A systematic review of psychiatric interventions on existing insomnia disorders was conducted primarily on insomnia disorders and the effects of CBT programs before the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) was published in 2014.^[14,27,28] In addition, subjects who undergo MM therapy are broadly classified as having mental disorders,^[29] and there is limited research that clearly defines the subject as having a sleep disorder or insomnia. Thus, there is a lack of a systematic review of the effectiveness of mindfulness meditation (MM) and CBT, which is a psychological intervention program that modifies behavior by controlling the mind. This study will investigate the clinical efficacy of programs of standardized MM and CBT for solving the sleep disorders using findings studies published by June 2018.

We believe that the results of this systematic review and meta-analysis will help clinicians optimize treatment protocols for patients with insomnia introduce safe and effective insomnia disorders treatment strategies for use in clinical settings.

2. Methods and analysis

2.1. Study registration

The protocol for this systematic review has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number, CRD42018111217) on October

10, 2018. We will conduct a systematic review according to this protocol, but if protocol amendments occur, the dates, changes, and rationale for each amendment will be tracked in PROSPERO. This protocol is reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 statement^[30] and the Cochrane Handbook for Systematic Reviews of Interventions.^[31,32]

2.2. Data sources and search strategy

The research strategy using domestic and foreign databases will be conducted by 2 researchers and methodologists. Six English-language databases (MEDLINE via PubMed, EMBASE via Elsevier, the Cochrane Central Register of Controlled Trials, the Allied and Complementary Medicine Database via EBSCO, the Cumulative Index to Nursing and Allied Health Literature via EBSCO, and PsycARTICLES via ProQuest) and 5 Korean-language databases (Oriental Medicine Advanced Searching Integrated System, Korean studies Information Service System, Research Information Service System, Korean Medical Database, and Korea Citation Index) will be searched.

We will also search the reference lists of the relevant articles and perform a manual search on Google Scholar to identify any potential additional studies. We will also include Standard and Ideal as well as Core within the search range suggested by the COSI model proposed by the National Library of Medicine. According to the COSI model, we will include not only the literature published in journals but also "gray literature" such as theses and conference proceedings. There will be no language restriction and the period will be set from 2008 to August 2018.

The search terms will be composed of the participant term part (e.g., "Insomnia disorder and Insomnia") and the intervention term part (e.g., Mindfulness or MM or Cognitive Behavior Therapy or CBT or MBSR^[33,34] or MCBT). The search strategies for MEDLINE and EMBASE are shown in Table 1 and will be modified and used similarly for the other databases.

2.3. Inclusion criteria

2.3.1. Types of studies. We will only include randomized controlled trials (RCTs). Studies using inappropriate random sequence generation methods such as alternate allocation or birth day will be excluded. If only the expression "randomization" (that the heart governs the mind) is mentioned without the randomization methods, it will be considered an RCT and will be included in this review.

Table 1
Search strategies for the MEDLINE and EMBASE.

[MEDLINE]
#1. "insomnia disorder"[MeSH Terms] OR "insomnia"[MeSH Terms] OR sleep disorder OR insomnia sleep disorder
#2. "mindfulness"[MeSH Terms] OR "mindfulness meditation"[MeSH Terms] OR "MBSR"[MeSH Terms] OR mindfulness based
#3. "CBT"[MeSH Terms] OR cognitive behavioral therapy
#4. (#1 OR #2) AND (#1 OR #3) AND (#1 AND #2 AND #3)
[EMBASE]
#1. "insomnia"/exp OR "insomnia disorder"
#2. sleep disorder
#3. "mindfulness" OR "meditation" OR "MBSR" OR mindfulness-based meditation OR "mindfulness-based"
#4. "CBT" OR "cognitive behavioral therapy"
#5. (#1 OR #3) AND (#1 OR #3 OR #4) AND (#1 AND #2 AND #3)

Table 2**The studies analytical criteria factors and framework (search strategies using PICO).**

Criteria factor	Standard contents
Research method	RCT studies as a quantitative research method (except for retrospective studies; in vivo, in vitro, case reports or studies; qualitative studies; and uncontrolled trials)
Research design	RCT studies
Purpose	Presearch purposes should be revealed.
Participants/patients	Participants with a diagnosis of insomnia sleep disorder using standardized diagnostic tools such as the DSM-5. There will be no restriction on the sex or race of the participants.
Intervention/moderate variables	Mindfulness-based meditation programs, cognitive behavioral therapy programs
Comparator	There is no restriction.
Outcomes	-Effect on sleep time (total sleep time, ^[35] sleep onset latency, ^[36,37] wake after sleep onset, ^[38] sleep efficiency) -Effect on quality of sleep (Pittsburgh Sleep Quality, ^[39] Insomnia Severity Index, The Medical Outcome Study Sleep Scale, Stanford Sleep Questionnaire, Women's Health Initiative Insomnia Rating Scale, The Sleeping Instrument A)
Data statistics	Different statistics such as mean, standard deviation, t- and f-values, effect size calculations

This study will include systematic review studies, in which structured MM programs and CBT programs are conducted for at least 6 weeks and medical outcomes such as sleep quality and sleep time are present. However other designs such as in vivo, in vitro, case reports or studies, retrospective studies, qualitative studies, and uncontrolled trials will be excluded, as will all studies that fail to provide detail results.

In brief, the search strategies using the patient/participants/population/problem, intervention, comparison, outcome (PICO) and timing (setting, setting, and study design) approach are shown in Table 2.

2.3.2. Types of participants. We will include studies on patients, aged 20 to 60 years, with a diagnosis of insomnia or sleep disorders^[40] using standardized diagnostic tools such as the DSM-5. There will be no restriction on the sex or race of the participants. However, studies will be excluded if the participants have other serious illnesses, such as severe physical illness or findings suggesting a medical condition (e.g., abnormal clinical laboratory test, ECG, Chest PA, and vital sign) such as Parkinson's disease.

2.3.3. Types of interventions. The intervention methods included in this study are standardized MM programs and CBT programs. There are no other restrictions regarding the control intervention.

2.3.4. Types of outcome measures. The primary outcome measures are as follows:

Primary care outcomes were reported using the following measures of change in sleep time and sleep quality:

a. Effect on sleep time

1. An activity recorder (Actigraphy)^[41] that records activity during sleep worn on the wrist or ankle
2. Polysomnography^[42] test, which is a medical examination that measures the physiological changes by measuring EEG^[43], EMG, EEG, ECG, snoring, and respiration, that is used to diagnose a disorder
3. A sleep diary is used to measure the patient's sleep habits, sleep hygiene, and sleep problems for 2 weeks and to evaluate the progress of the treatment.

We will measure the following sleep variables: total sleep time,^[44,45] sleep onset latency,^[36,37,45] wake after sleep onset, and sleep efficiency^[46] by using the above tools.

b. Effect on quality of sleep

- (1) Pittsburgh Sleep Quality^[39,47] is a questionnaire for measuring sleep quality and discomfort for the past

month. It consists of 7 subfactors and scores from 0 to 21 points.

- (2) Insomnia Severity Index was developed to assess insomnia and is a 5-point cut-off self-report scale consisting of a total of 7 items. A higher score represents more severe insomnia.
- (3) The Medical Outcome Study Sleep Scale is composed of 12 items, measured in the range of 0 to 100, and the lower the score, the better the quality of sleep.
- (4) Stanford Sleep Questionnaire is a 7-level scale with subjective sleepiness ranging from 1 to 7, with lower scores indicating improved sleep quality.
- (5) Women's Health Initiative Insomnia Rating Scale consists of a 5-item scale for evaluating subjective sleep quality for sleep initiation and maintenance, the lower the score, the better the quality of sleep.
- (6) The sleeping instrument A consists of 15 items and measures 4 points. Ranging from a minimum score of 15 to a maximum score of 60, with higher scores representing better sleep.

The secondary outcome measures are as follows:

Secondary medical outcomes including depression, stress, anxiety, decreased fatigue, and quality of life measured using the Hamilton Depression Scale,^[48] Beck Depression Inventory,^[49] Perceived Stress Scale,^[50,51] State-Trait Anxiety Inventory State Version,^[52] Quality of life as measured by validated assessment tools such as the Stroke Specific Quality of Life Scale,^[53] 36-Item Short Form Health Survey,^[54] and Fatigue-FSI.^[55]

2.4. Study selection

The study selection will be conducted by 2 independent researchers according to the aforementioned selection criteria. After removing duplicates, we will review the titles and abstracts of the searched studies for relevance and then evaluate the full texts of the remaining studies for eligibility. Any disagreement on study selection will be resolved through discussion with other researchers and reviewers. The literature selection process will be reported in accordance with the PRISMA guidelines.^[56]

2.5. Data extraction

Two independent researchers, using a standardized data collection form, will perform and cross check the data extraction. Discrepancies will be resolved through discussion with other researchers. The extracted items will include the first author's name; year of publication; country; sample size and number of dropouts; details about the participants, intervention, and

comparisons or control; duration of the intervention and main outcomes; and adverse effects. Two independent researchers will then organize and code the extracted data using Excel 2007 (Microsoft, Redmond, WA) that will then be shared among researchers using Dropbox (Dropbox, Inc., CA) folders. If the obtained data are insufficient or ambiguous, we will contact the corresponding authors of the included studies via e-mail to request additional information.

2.6. Quality assessment

2.6.1. Assessment of risk of bias. We will independently assess the risk of bias using Cochrane's assessment of risk of bias.^[57]

Two independent researchers will assess the methodological quality of the included studies and the quality of evidence for each

main finding. Discrepancies will be resolved through discussion with other researchers.

To assess the evidence of RCT-based studies, we will assess the random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, selective reporting, and other biases for each included study. Each domain will be categorized into one of 3 groups: "yes means low risk," "unclear means insufficient information," and "no means high risk." Each evaluation will be recorded in an Excel 2007 (Microsoft) spreadsheet and will be shared among researchers in Dropbox (Dropbox Inc) folders. The evaluated results will be presented in a full review using Review Manager Version 5.3 (Cochrane, London, UK). The list used for the assessment of the risk of bias is shown in Table 3.

Table 3

Cochrane's assessment of risk of bias.

Item		Criteria
Sequence generation	Yes	<ul style="list-style-type: none"> Referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots, minimization*
	No	<ul style="list-style-type: none"> Using an open random allocation schedule (e.g., a list of random numbers), assignment envelopes were used without appropriate safeguards, alternation or rotation, date of birth, case record number, any other explicitly unconcealed procedure
Allocation Concealment	Yes	<ul style="list-style-type: none"> No blinding, but the review authors judge that the outcome and outcome measurements are not likely to be influenced by lack of blinding; Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias
	No	<ul style="list-style-type: none"> No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken; Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias
Blinding	Yes	<ul style="list-style-type: none"> No blinding, but the review authors judge that the outcome and outcome measurements are not likely to be influenced by lack of blinding; Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias
	No	<ul style="list-style-type: none"> No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken; Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias
Incomplete outcome data	Yes	<ul style="list-style-type: none"> No missing outcome data; Reasons for missing outcome data unlikely to be related to true outcome Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; For continuous outcome data, plausible effect size among missing outcomes not enough to have a clinically relevant impact on observed effect size; Missing data have been imputed using appropriate methods
	No	<ul style="list-style-type: none"> Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; For continuous outcome data, plausible effect size among missing outcomes enough to induce clinically relevant bias in observed effect size; "As-treated" analysis performed with substantial departure of the intervention received from that assigned at randomization; Potentially inappropriate application of simple imputation
Selective outcome reporting	Yes	<ul style="list-style-type: none"> The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified
	No	<ul style="list-style-type: none"> Not all of the study's pre-specified primary outcomes have been reported; One or more primary outcomes is reported using measurements, analysis methods, or subsets of the data (e.g., subscales) that were not pre-specified; One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; The study report fails to include results for a key outcome that would be expected to have been reported for such a study
Other potential threats to validity	Yes	<ul style="list-style-type: none"> Had a potential source of bias related to the specific study design used; or Stopped early due to some data-dependent process (including a formal-stopping rule); or Had extreme baseline imbalance; or Has been claimed to have been fraudulent; or Had some other problem
	No	<ul style="list-style-type: none"> Insufficient information to assess whether an important risk of bias exists; Insufficient rationale or evidence that an identified problem will introduce bias

* Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

2.7. Data synthesis and analysis

The data synthesis and analysis will be performed using Review Manager Version 5.3 and CMA 2.0 (Comprehensive Meta-Analysis software 2.0) and shared among researchers in Dropbox folders. Descriptive analyses of the details of the participants, interventions, and outcomes will be conducted for all included studies. A quantitative synthesis will be performed if there are studies using the same types of intervention, comparison, and outcome measures. The data will be pooled as the mean difference or standardized mean difference with 95% confidence intervals (CIs) for continuous outcomes. The heterogeneity of effect sizes will be assessed using the I-squared statistic. We will consider I-squared values greater than 50% and 75% indicative of substantial and high heterogeneity, respectively. In the meta-analyses, a random effects model will be used when the heterogeneity is significant (an I-squared value >75%), while a fixed effects model will be used when the heterogeneity is non-significant. A fixed effects model will be also used when the number of studies included in the meta-analysis is very small, where inter-study variance estimates have poor accuracy.^[58,59] When it is believed that the heterogeneity is too high for the results to be synthesized (an I-squared value >75%), a subgroup analysis will be conducted as follows to determine the cause of heterogeneity.

2.8. Subgroup analysis

If the heterogeneity is evaluated as significant (an I-squared value >75%) and the necessary data are available, we will conduct a subgroup analysis to account for the heterogeneity. A subgroup analysis will be conducted according to the following criteria:

- (1) the intervention program kind;
- (2) the intervention program period and time; and
- (3) controls and comparators.

2.9. Sensitivity analysis

To identify the robustness of the meta-analysis result, we will perform sensitivity analyses by determining the effects of excluding

- (1) studies with high risks of bias,
- (2) studies with missing data, and
- (3) outliers.

2.10. Assessment of reporting bias

If there are more than 10 trials included in the analysis, reporting biases such as publication bias will be assessed by using funnel plots. When reporting bias is implied by funnel plot asymmetry, we will attempt to explain possible reasons.

3. Ethics and dissemination

Ethical approval will not be needed because the data used in this systematic review will not be individual patient data and there will be no concerns regarding privacy. The results will be disseminated by the publication of a manuscript in a peer-reviewed journal or presentation at a relevant conference.

4. Discussion

Insomnia disorder is one of the most common illnesses in modern populations. If insomnia persists, it causes a decline in productivity and quality of life.^[60] Thus, if patients with

insomnia are not adequately treated,^[15,61] it may persist for years after onset.^[62] The patients who are treated for insomnia in clinical practice are mainly prescribed medication.^[61] However, the drug prescribed should be considered with the patient's characteristics, such as the cause, duration, and intensity of the patient's insomnia. Long-term treatment with medication may also increase patient dependence.^[63] Therefore, the sleep disorder is an involuntary disease that cannot be cured by medication but cannot be controlled by the will of the individual and it is changing the perception that it is a disorder that requires therapeutic intervention. And in clinical view, it has avoided the side effects of drugs and increased the use of various programs using psychological interventions in a safe environment.

Therefore, recently, the number of studies on MM and CBT, psychological interventions used to treat insomnia disorder has increased.^[14,19] In addition, this psychological intervention can actually prove and show the correlation between psychology and behavior, that is, human cognition, behavior, and emotion.^[64] The purpose of this study is to investigate the clinical efficacy of standardized MM and CBT^[47,65,66] programs for solving the sleep problems of the subjects with insomnia using data from studies published by June 2018. We believe that the results of this systematic review will enable clinicians to optimize treatment protocols for patients with insomnia and to introduce safe and effective sleep disorder treatment strategies for use in clinical settings. The results of this review will also provide a broader evidence base for psychological intervention beside pharmacotherapy for patients with insomnia. In addition, policy makers will be able to confirm the effectiveness of MM and CBT^[47] programs as therapeutic interventions, which are currently covered by public insurance. Finally, it is expected that it will be possible to provide basic data for the scientific theory of ShimJuShinJi (that the heart governs the mind),^[64] demonstrating the correlation between mind and body, which is the viewpoint of Oriental medicine.

Author contributions

The study was conceptualized by CMJ. The protocol was drafted by CMJ and KHW. The search strategy was developed by CMJ, KHW, and LGE. LGE, KSI, KHK, JHI, KYS, and KJH revised the manuscript. BHG submitted the manuscript for publication. All authors have read and approved the final manuscript.

Conceptualization: Moon Joo Cheong, Go-Eun Lee, Hyung Won Kang.

Data curation: Moon Joo Cheong.

Formal analysis: Moon Joo Cheong.

Funding acquisition: Hyung Won Kang.

Investigation: Moon Joo Cheong.

Methodology: Moon Joo Cheong.

Resources: Moon Joo Cheong, Hyung Won Kang.

Software: Moon Joo Cheong.

Validation: Moon Joo Cheong.

Visualization: Moon Joo Cheong.

Writing – original draft: Moon Joo Cheong, Hyung Won Kang.

Writing – review & editing: Moon Joo Cheong, Go-Eun Lee, Hyung Won Kang, Sooim Kim, Hye Kyung Kim, Han-ik Jo, Yeonseok Kang, Jae-Hyo Kim, Hyeon-Gi Baek.

Hyung Won Kang orcid: 0000-0001-6497-0100.

References

- [1] Smagula SF, Stone KL, Fabio A, et al. Risk factors for sleep disturbances in older adults: evidence from prospective studies. *Sleep Med Rev* 2016;25:21–30.

- [2] Perlis ML, Smith LJ, Lyness JM, et al. Insomnia as a risk factor for onset of depression in the elderly. *Behav Sleep Med* 2006;4:2:104–13.
- [3] Kang M-R, Choi SJ, Joo EY. Sleep disorders documented by night polysomnography in patients with chronic insomnia disorder. *J Korean Neurol Assoc* 2018;36:1–8.
- [4] Seo S-Y. Subjective and objective evaluation of sleep disorders. *Korean Psychol Assoc Conf Proc* 2018;185.
- [5] Available at: <http://www.nhis.or.kr/menu/boardRetriveMenuSet.xx?menuId=F3321> (a statistical office).
- [6] Dong L, et al. Treatment agreement, adherence, and outcome in cognitive behavioral treatments for insomnia. *J Consult Clin Psychol* 2018;86:294–9.
- [7] Skarpsno ES, Nilsen TIL, Sand T, et al. Do physical activity and body mass index modify the association between chronic musculoskeletal pain and insomnia? Longitudinal data from the HUNT study, Norway. *J Sleep Res* 2018;27:32–9.
- [8] Galinsky AM, Ward BW, Joestl SS, et al. Sleep duration, sleep quality, and sexual orientation: findings from the 2013–2015 National Health Interview Survey. *Sleep Health* 2018;4:56–62.
- [9] Rosekind MR, Gregory KB, Mallis MM, et al. The cost of poor sleep: workplace productivity loss and associated costs. *J Occup Environ Med* 2010;52:91–8.
- [10] Rosekind MR, Gregory KB. Insomnia risks and costs: health, safety, and quality of life. *Am J Manag Care* 2010;16:617–26.
- [11] Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. *Sleep* 2009;32:55–64.
- [12] Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. *J Clin Psychiatry* 2005;66:469–76.
- [13] Blumenthal H, et al. The links between social anxiety disorder, insomnia symptoms, and alcohol use disorders: findings from a large sample of adolescents in the United States. *Behav Ther* 2018; <https://doi.org/10.1016/j.beth.2018.03.010>. Accessed December 2018.
- [14] Adams RJ, Appleton SL, Taylor AW, et al. Sleep health of Australian adults in 2016: results of the 2016 Sleep Health Foundation national survey. *Sleep Health* 2017;3:35–42.
- [15] Wang M-Y, Wang S-Y, Tsai P-S. Cognitive behavioural therapy for primary insomnia: a systematic review. *J Adv Nurs* 2005;50:553–64.
- [16] Kao C-C, Huang CJ, Wang MY, et al. Insomnia: prevalence and its impact on excessive daytime sleepiness and psychological well-being in the adult Taiwanese population. *Quality Life Res* 2008;17:1073–80.
- [17] Winbush NY, Gross CR, Kreitzer MJ. The effects of mindfulness-based stress reduction on sleep disturbance: a systematic review. *Explore* 2007;3:585–91.
- [18] Ong JC, Shapiro SL, Manber R. Combining mindfulness meditation with cognitive-behavior therapy for insomnia: a treatment-development study. *Behav Ther* 2008;39:171–82.
- [19] Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). *Sleep* 2006;29:1398–414.
- [20] Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. *Sleep* 2008;31:489–95.
- [21] Ong JC, Shapiro SL, Manber R. Mindfulness meditation and cognitive behavioral therapy for insomnia: a naturalistic 12-month follow-up. *Explore (NY)* 2009;5:30–6.
- [22] Ong JC, Manber R, Segal Z, et al. A randomized controlled trial of mindfulness meditation for chronic insomnia. *Sleep* 2014;37:1553–63.
- [23] Kabat-Zinn J. Mindfulness-based interventions in context: past, present, and future. *Clin Psychol Sci Pract* 2003;10:144–56.
- [24] Ludwig DS, Kabat-Zinn J. Mindfulness in medicine. *JAMA* 2008;300:1350–2.
- [25] Shapiro SL, Bootzin RR, Figueredo AJ, et al. The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer: an exploratory study. *J Psychosom Res* 2003;54:85–91.
- [26] Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. *J Clin Sleep Med* 2009;5:28–33.
- [27] Howell AJ, Digdon NL, Buro K. Mindfulness predicts sleep-related self-regulation and well-being. *Personal Individ Differ* 2010;48:419–24.
- [28] Mitchell MD, Gehrman P, Perlis M, et al. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. *BMC Family Pract* 2012;13:13–40.
- [29] Trauer JM, Qian MY, Doyle JS, et al. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. *Ann Int Med* 2015;163:191–204.
- [30] Chiesa A, Serretti A. Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. *Psychiatry Res* 2011;187:441–53.
- [31] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 elaboration and explanation. *BMJ* 2015;350:g7647–56.
- [32] Roland PS, Rosenfeld RM, Brooks LJ, et al. Clinical practice guideline: polysomnography for sleep-disordered breathing prior to tonsillectomy in children. *Otolaryngol Head Neck Surg* 2011;151–5.
- [33] Lee BK. The effects of mindfulness-based stress reduction (MBSR) program on pain and anxiety in cancer patients. *Korean Soc Stress Med* 2013;21:263–74.
- [34] Shahid A, Wilkinson K, Marcu S. Women's health initiative insomnia ratingscale (WHIIRS). In: STOP, THAT and one hundred other sleep scales. Springer, New York, NY;2011:403–404.
- [35] Haythornthwaite JA, Hegel MT, Kerns RD. Development of a sleep diary for chronic pain patients. *J Pain Symptom Manag* 1991;6:65–72.
- [36] Buysse DJ, Ancoli-Israel S, Edinger JD, et al. Recommendations for a standard research assessment of insomnia. *Sleep* 2006;29:1155–73.
- [37] Haynes SN, Adams A, Franzen M. The effects of presleep stress on sleep-onset insomnia. *J Abnorm Psychol* 1981;90:601.
- [38] Gross RT, Borkovec TD. Effects of a cognitive intrusion manipulation on the sleep-onset latency of good sleepers. *Behav Ther* 1982;13:112–6.
- [39] Buysse DJ, Reynolds CFIII, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193–213.
- [40] Krouse HJ, Davis JE, Krouse JH. Immune mediators in allergic rhinitis and sleep. *Otolaryngol Head Neck Surg* 2002;126:607–13.
- [41] Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0. The Cochrane Collaboration, 2011, 33–49.
- [42] Lichstein KL, Stone KC, Donaldson J, et al. Actigraphy validation with insomnia. *Sleep* 2006;29:232–9.
- [43] Ge L, Jung MS, Lee SI, et al. Analysis of quantitative electroencephalography (QEEG) following acupuncture treatment in patients with insomnia: Z scored absolute power and sLORETA. *J Oriental Neuropsychiatry* 2016;27:169–84.
- [44] Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. *Sleep* 2012;35:287–302.
- [45] MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. *Biol Psychiatry* 1991;30:371–6.
- [46] Wilson DL, Barnes M, Ellett L, et al. Decreased sleep efficiency, increased wake after sleep onset and increased cortical arousals in late pregnancy. *AustN Z J Obstet Gynaecol* 2011;51:38–46.
- [47] Monk TH, Reynolds CFIII, Kupfer DJ, et al. The Pittsburgh sleep diary. *J Sleep Res* 1994;3:111–20.
- [48] Oh JJ, Song MS, Kim SM. Development and validation of Korea sleep scale A. *J Korean Acad Nurs* 1998;28:563–72.
- [49] Bech P, Allerup P, Gram LF, et al. The Hamilton Depression Scale: evaluation of objectivity using logistic models. *Acta Psychiatrica Scandinavica* 1981;63:290–9.
- [50] Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio 1996;78:490–8.
- [51] Cohen S., Kamarck T., Mermelstein R. Perceived stress scale. Measuring stress: A guide for health and social scientists, 1994;235–283.
- [52] Remor E. Psychometric properties of a European Spanish version of the Perceived Stress Scale (PSS). *Spanish J Psychol* 2006;9:86–93.
- [53] AL-Yateem N, Brenner M. Validation of the short state trait anxiety inventory (Short STAI) completed by parents to explore anxiety levels in children. *Compr Child Adolesc Nurs* 2017;40:29–38.
- [54] Williams LS, Weinberger M, Harris LE, Clark DO, et al. Development of a stroke-specific quality of life scale. *Stroke* 1999;30:1362–9.
- [55] Ware JR, John E, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. *Medical Care* 1992;30:473–83.
- [56] Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. *Eur J Cancer* 2002;38:27–43.
- [57] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Rev* 2015;4:1–9.
- [58] Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0. Cochrane Collab 2011;33–49.

- [59] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Br Med J* 2003;327:557–60.
- [60] Furukawa TA, Watanabe N, Omori IM, et al. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. *JAMA* 2007;297:465–70.
- [61] Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. *Depress Anxiety* 2003;18:163–76.
- [62] Soares CN. Insomnia in women: an overlooked epidemic. *Arch Women Ment Health* 2005;8:205–13.
- [63] Smolensky MH, et al. Sleep disorders, medical conditions, and road accident risk. *Accident Anal Prevent* 2011;43:533–48.
- [64] Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. *Am J Med* 2006;119:463–9.
- [65] Kim JH. Types of mindfulness meditation and their implications for cognitive behavioral therapy. *Cognitive Behav Pract* 2004;4:27–44.
- [66] Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the medical outcomes study sleep measure. *Sleep Med* 2005;6:41–4.